Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTITUSSIVE vs DEXTROMETHORPHAN POLISTIREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
FDA-approved: Symptomatic relief of nonproductive cough,Off-label: Cough associated with upper respiratory tract infections, chronic bronchitis, COPD
Symptomatic relief of nonproductive cough associated with upper respiratory tract infections,Off-label: Management of pseudobulbar affect (with quinidine),Off-label: Treatment of neuropathic pain
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Metabolism varies by agent: Dextromethorphan is metabolized via CYP2D6; codeine (opioid antitussive) is metabolized via CYP2D6 to morphine; benzonatate is metabolized by plasma esterases.
Hepatic via CYP2D6 (O-demethylation to dextrorphan, active metabolite). Also undergoes N-demethylation via CYP3A4. Polymorphic metabolism (poor metabolizers at risk of toxicity).
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Approximately 35-45% bound to plasma albumin.
~50% bound; primarily to albumin
Vd approximately 3-5 L/kg, indicating extensive tissue distribution.
Vd: ~5–6 L/kg; clinical meaning: extensive tissue distribution, including CNS
Oral: approximately 40-50% due to first-pass metabolism.
Oral (polistirex): approximately 50–60% (first-pass metabolism reduces systemic availability)
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, avoid if possible.
No specific dosing adjustment provided for dextromethorphan polistirex; use with caution in severe renal impairment (Cr Cl < 30 m L/min) due to potential accumulation of metabolites.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific dosing adjustment provided; use with caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
Dextromethorphan: 2-6 years: 2.5-5 mg every 4-6 hours; 6-12 years: 5-10 mg every 4-6 hours; >12 years: adult dose. Codeine: not recommended for children due to safety concerns.
Children 6-12 years: 15-30 mg orally every 12 hours; not to exceed 60 mg in 24 hours. Children 2-5 years: 7.5-15 mg orally every 12 hours; not to exceed 30 mg in 24 hours. Not recommended under 2 years.
Initiate at lowest effective dose; monitor for sedation, constipation, and falls; avoid codeine if possible; dextromethorphan: 10 mg every 6-8 hours.
Elderly patients may be more sensitive to anticholinergic effects; use the lowest effective dose and monitor for adverse effects such as sedation and dizziness.
N/A (No black box warning for general antitussives; specific agents like benzonatate have warnings for severe allergic reactions and accidental ingestion in children.)
No FDA black box warning.
Do not exceed recommended dosage (risk of toxicity, especially with dextromethorphan abuse).,Caution in patients with respiratory depression, asthma, or chronic cough due to smoking or COPD.,Avoid in children <2 years (risk of serious adverse events).
Do not use with MAOIs or within 14 days of stopping MAOIs,Risk of serotonin syndrome when used with serotonergic drugs,Caution in patients with G6PD deficiency, hepatic impairment, or chronic cough associated with smoking, asthma, or emphysema,QT prolongation risk at supratherapeutic doses,Misuse potential with high doses causing dissociative effects
Hypersensitivity to the specific antitussive agent.,Concomitant use of MAOIs or within 14 days (risk of serotonin syndrome with dextromethorphan).,Respiratory depression (especially opioid-containing antitussives).
Concurrent use or within 14 days of MAOIs,Hypersensitivity to dextromethorphan or any component,Use in children under 2 years of age (OTC products)
Grapefruit juice may increase absorption of dextromethorphan, potentially increasing side effects. Avoid alcohol as it enhances CNS depression. No specific food restrictions for codeine, but avoid high-tyramine foods if taking MAOIs concurrently.
Avoid grapefruit and grapefruit juice as they may alter metabolism. Take with or without food; food does not significantly affect absorption.
Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal respiratory depression and withdrawal if used near term; possible association with congenital malformations in first trimester, but evidence inconclusive. Avoid use in first trimester and near term.
No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoid use in first trimester due to theoretical risk based on weak NMDA antagonism.
Dextromethorphan: Low levels in breast milk; M/P not established; generally compatible. Codeine: M/P ratio ~2.5; risk of CNS depression in infant; use caution or avoid. Monitor infant for sedation.
Limited data; excreted in human breast milk in low amounts (M/P ratio not established). Theoretical risk of CNS depression in infant. Use with caution, especially in neonates or preterm infants. Consider immediate-release formulations if necessary.
No specific pharmacokinetic changes require dose adjustment for dextromethorphan. Codeine metabolism may be altered due to pregnancy-induced changes in CYP2D6; individual dose titration recommended, but avoid use if possible.
No specific dose adjustments recommended for pregnancy; however, use lowest effective dose due to altered pharmacokinetics (increased volume of distribution, decreased plasma protein binding) potentially leading to reduced peak concentrations but unchanged half-life.
Antitussives like dextromethorphan are effective for nonproductive cough but should not be used in patients with chronic productive cough due to potential suppression of necessary mucus clearance. Abuse potential exists with dextromethorphan at high doses; monitor for serotonin syndrome when combined with MAOIs or SSRIs. Codeine-containing antitussives require caution in CYP2D6 ultra-rapid metabolizers due to risk of morphine toxicity.
Dextromethorphan polistirex is an extended-release formulation allowing twice-daily dosing. Its antitussive effect lasts up to 12 hours. Caution in patients with asthma or COPD as it may reduce mucociliary clearance. Avoid concurrent use with MAOIs due to risk of serotonin syndrome. Not effective for chronic cough and should not be used for more than 7 days.
Take only for dry, hacking cough; do not use for cough with phlegm unless directed by a doctor.,Do not exceed recommended dose; excessive use can lead to serious side effects including confusion, hallucinations, and rapid heart rate.,Avoid alcohol and sedatives as they may increase drowsiness and respiratory depression.,Seek medical attention if cough persists >1 week, or is accompanied by fever, rash, or headache.,Do not combine with other cough/cold products containing the same active ingredients.
Do not crush or chew the extended-release capsules or suspension; swallow whole or shake suspension well before use.,Do not exceed recommended doses; may cause drowsiness, avoid driving or operating machinery.,Discontinue use and consult healthcare provider if cough persists more than 7 days or is accompanied by fever, rash, or headache.,Avoid alcohol and other CNS depressants as they may increase sedation.,Inform healthcare provider if you are taking MAOIs (e.g., for depression, Parkinson's) or SSRIs to avoid serotonin syndrome.,Keep out of reach of children; overdose can be fatal.
No interactions on record
"The combination of dextromethorphan, a centrally acting antitussive with NMDA receptor antagonist and sigma-1 receptor agonist properties, and aceprometazine, a phenothiazine neuroleptic with strong antihistaminergic and moderate anticholinergic and antidopaminergic effects, can result in additive central nervous system depression. This interaction may lead to excessive sedation, respiratory depression, impaired psychomotor function, and an increased risk of falls or cognitive impairment, particularly in elderly or debilitated patients. Concurrent use may also lower the seizure threshold, especially in patients with predisposing factors."
"Dextromethorphan, a serotonergic agent metabolized by CYP2D6, when combined with cariprazine, a dopamine D3/D2 receptor partial agonist, may increase the risk of serotonin syndrome due to additive serotonergic effects. Cariprazine can inhibit CYP2D6, reducing dextromethorphan clearance and elevating its plasma concentration, leading to enhanced serotonin activity. Clinically, patients may present with altered mental status, autonomic instability, and neuromuscular abnormalities."
"Dextromethorphan inhibits CYP2B6 and CYP2C9, which are involved in valproic acid metabolism. This results in decreased valproic acid clearance, potentially elevating valproic acid serum concentrations and increasing the risk of dose-dependent adverse effects such as hepatotoxicity, thrombocytopenia, and sedation. Concurrent use requires dose adjustment and close monitoring for signs of valproate toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTITUSSIVE vs DEXTROMETHORPHAN POLISTIREX, answered by our medical review team.
ANTITUSSIVE is a Antitussive that works by Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).. DEXTROMETHORPHAN POLISTIREX is a Antitussive that works by Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTITUSSIVE and DEXTROMETHORPHAN POLISTIREX depend on the specific clinical indication. These are both Antitussive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTITUSSIVE is: For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.. The standard adult dose of DEXTROMETHORPHAN POLISTIREX is: 30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTITUSSIVE and DEXTROMETHORPHAN POLISTIREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTITUSSIVE is classified as Category C. Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal . DEXTROMETHORPHAN POLISTIREX is classified as Category C. No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.